Pluristem Therapeutics Inc. (PSTI)
Price:
1.00 USD
( - -0.03 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Genmab A/S
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
NEWS
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
zacks.com
2022-07-14 12:24:04Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery
benzinga.com
2022-07-13 09:59:02Pluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary endpoint, the Short.
Best Penny Stocks to Buy as January Ends? 4 to Watch
pennystocks.com
2022-01-22 11:30:00Here are four penny stocks to add to your end of January watchlist The post Best Penny Stocks to Buy as January Ends? 4 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks to Buy Right Now? 3 For Your List in January
pennystocks.com
2022-01-10 10:38:56Check these three penny stocks out for your January watchlist The post Best Penny Stocks to Buy Right Now? 3 For Your List in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform
benzinga.com
2022-01-10 06:26:32Pluristem Therapeutics Inc (NASDAQ: PSTI) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry. Tnuva Group is the largest food producer in Israel and the Israeli player in the field of alternative dairy and protein products.
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
zacks.com
2021-12-28 13:48:12Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.
Pluristem CEO Issues Shareholder Update
globenewswire.com
2021-09-22 08:15:00HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay.
Pluristem Appoints Prof. Varda Shalev MD and Mr.
globenewswire.com
2021-07-19 07:00:00HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the Tel Aviv University's School of Public Health, and Mr. Doron Birger, a high-tech industry executive with a background in bringing groundbreaking products to market.
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
globenewswire.com
2021-07-08 07:10:00HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company announced today that it is bringing its Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 Phase II studies to clinical readout. The Company's COVID-19 program included over 100 patients across two Phase II studies in the U.S., Europe and Israel, and in compassionate use and expanded access programs in the U.S. and Israel. The analysis will be based on 89 patients enrolled in the previously announced two Phase II studies, which investigated the safety and efficacy of Pluristem's PLX cells as a treatment for severe COVID-19 cases complicated by ARDS.
Cathie Wood's ARK Invest Sells 194,000 Shares of Pluristem Therapeutics
247wallst.com
2021-06-05 07:53:36One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 194,000 shares of Pluristem Therapeutics Inc.
Pluristem Stock is Trading Higher After €20M Non-Dilutive Funding from European Investment Bank
benzinga.com
2021-05-25 08:48:36Pluristem Therapeutics Inc (NASDAQ: PSTI) has received €20 million (approximately $24 million) from the European Investment Bank (EIB), the first disbursement of three tranches of funding. The disbursement reflects that Pluristem has achieved a key milestone in a previously announced €50 million non-dilutive financing agreement.
PSTI Stock: From $4.52 To Over $4.90 Pre-Market Explanation
pulse2.com
2021-04-29 07:51:42The stock price of Pluristem Therapeutics Inc. (NASDAQ: PSTI) increased from $4.52 to over $4.90 pre-market. This is why it happened.
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
seekingalpha.com
2021-02-05 13:54:10Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
globenewswire.com
2021-02-02 08:30:00HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products (“Pluristem” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 4,761,905 shares of its common stock at a purchase price of $6.30 per share in a registered direct offering, for gross proceeds of $30 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about February 4, 2021, subject to the satisfaction of customary closing conditions.
ARKG: Potential Disruption For Healthcare And Pharma Industries
seekingalpha.com
2021-01-19 13:56:04ARKG: Potential Disruption For Healthcare And Pharma Industries
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem's ARDS Associated With COVID-19 Program to Mexico
globenewswire.com
2020-12-29 07:00:00HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has entered into a collaboration agreement with Mexican pharmaceutical company Innovare R&D to expand its ongoing clinical program of PLX cells in the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 in Mexico. The Phase II study in Mexico is subject to the approval of local authorities, with the goal of being conducted under the U.S. Food and Drug Administration (FDA) cleared protocol .
No data to display
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
zacks.com
2022-07-14 12:24:04Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery
benzinga.com
2022-07-13 09:59:02Pluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary endpoint, the Short.
Best Penny Stocks to Buy as January Ends? 4 to Watch
pennystocks.com
2022-01-22 11:30:00Here are four penny stocks to add to your end of January watchlist The post Best Penny Stocks to Buy as January Ends? 4 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks to Buy Right Now? 3 For Your List in January
pennystocks.com
2022-01-10 10:38:56Check these three penny stocks out for your January watchlist The post Best Penny Stocks to Buy Right Now? 3 For Your List in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform
benzinga.com
2022-01-10 06:26:32Pluristem Therapeutics Inc (NASDAQ: PSTI) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry. Tnuva Group is the largest food producer in Israel and the Israeli player in the field of alternative dairy and protein products.
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
zacks.com
2021-12-28 13:48:12Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.
Pluristem CEO Issues Shareholder Update
globenewswire.com
2021-09-22 08:15:00HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay.
Pluristem Appoints Prof. Varda Shalev MD and Mr.
globenewswire.com
2021-07-19 07:00:00HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the Tel Aviv University's School of Public Health, and Mr. Doron Birger, a high-tech industry executive with a background in bringing groundbreaking products to market.
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
globenewswire.com
2021-07-08 07:10:00HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company announced today that it is bringing its Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 Phase II studies to clinical readout. The Company's COVID-19 program included over 100 patients across two Phase II studies in the U.S., Europe and Israel, and in compassionate use and expanded access programs in the U.S. and Israel. The analysis will be based on 89 patients enrolled in the previously announced two Phase II studies, which investigated the safety and efficacy of Pluristem's PLX cells as a treatment for severe COVID-19 cases complicated by ARDS.
Cathie Wood's ARK Invest Sells 194,000 Shares of Pluristem Therapeutics
247wallst.com
2021-06-05 07:53:36One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 194,000 shares of Pluristem Therapeutics Inc.
Pluristem Stock is Trading Higher After €20M Non-Dilutive Funding from European Investment Bank
benzinga.com
2021-05-25 08:48:36Pluristem Therapeutics Inc (NASDAQ: PSTI) has received €20 million (approximately $24 million) from the European Investment Bank (EIB), the first disbursement of three tranches of funding. The disbursement reflects that Pluristem has achieved a key milestone in a previously announced €50 million non-dilutive financing agreement.
PSTI Stock: From $4.52 To Over $4.90 Pre-Market Explanation
pulse2.com
2021-04-29 07:51:42The stock price of Pluristem Therapeutics Inc. (NASDAQ: PSTI) increased from $4.52 to over $4.90 pre-market. This is why it happened.
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
seekingalpha.com
2021-02-05 13:54:10Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
globenewswire.com
2021-02-02 08:30:00HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products (“Pluristem” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 4,761,905 shares of its common stock at a purchase price of $6.30 per share in a registered direct offering, for gross proceeds of $30 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about February 4, 2021, subject to the satisfaction of customary closing conditions.
ARKG: Potential Disruption For Healthcare And Pharma Industries
seekingalpha.com
2021-01-19 13:56:04ARKG: Potential Disruption For Healthcare And Pharma Industries
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem's ARDS Associated With COVID-19 Program to Mexico
globenewswire.com
2020-12-29 07:00:00HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has entered into a collaboration agreement with Mexican pharmaceutical company Innovare R&D to expand its ongoing clinical program of PLX cells in the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 in Mexico. The Phase II study in Mexico is subject to the approval of local authorities, with the goal of being conducted under the U.S. Food and Drug Administration (FDA) cleared protocol .